Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Generic Group Tells New Department Of Pharmaceuticals That Industry Is Under Attack By Multinationals

This article was originally published in PharmAsia News

Executive Summary

With the setting up of a new Department of Pharmaceuticals, the Indian Pharmaceutical Alliance, a powerful lobby of the top 11 Indian generic drug makers, has upped its ante against brand-drug multinational companies

You may also be interested in...



Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies

MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations

Indian Pharma Lobby Begins Fresh Offensive For Cap On Foreign Investments Into Domestic Companies

MUMBAI - As India's commerce and finance ministries wrangle over the viability of capping investments by global pharmaceutical companies into Indian generic firms, the Indian Pharmaceutical Alliance led a new offensive urging the government to tighten investment regulations

Ranbaxy Alleges Rivals Of Meddling With Daiichi Sankyo Deal; U.S. House Committee Enters Fray

MUMBAI - India's leading drug maker Ranbaxy Laboratories has alleged that global big pharma players are trying to scuttle its acquisition by Daiichi Sankyo. U.S. FDA and the U.S. Department of Justice's probe of Ranbaxy is part of a larger battle against the company, CEO Malvinder Singh said in a television interview on Friday, indicating that vested interests in the global industry were trying to stall the deal

Related Content

UsernamePublicRestriction

Register

SC069062

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel